Horizon Therapeutics (HPTX) & Syndax Pharmaceuticals (SNDX) Head-To-Head Analysis

Horizon Therapeutics (NASDAQ: HPTX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap biopharmaceuticals companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Profitability

This table compares Horizon Therapeutics and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Syndax Pharmaceuticals -4,304.34% -57.90% -45.09%

Analyst Ratings

This is a breakdown of current ratings and target prices for Horizon Therapeutics and Syndax Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Syndax Pharmaceuticals 0 0 8 0 3.00

Syndax Pharmaceuticals has a consensus price target of $26.43, indicating a potential upside of 178.78%. Given Syndax Pharmaceuticals’ higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Horizon Therapeutics.

Valuation & Earnings

This table compares Horizon Therapeutics and Syndax Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Horizon Therapeutics N/A N/A N/A ($0.03) -1,533.00
Syndax Pharmaceuticals $1.22 million 189.52 -$44.47 million ($2.83) -3.35

Horizon Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Horizon Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

59.9% of Syndax Pharmaceuticals shares are owned by institutional investors. 24.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Syndax Pharmaceuticals beats Horizon Therapeutics on 6 of the 10 factors compared between the two stocks.

Horizon Therapeutics Company Profile

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply